

Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A method for inducing an immune response comprising the step of applying to the unbroken surface of the skin a composition comprising a particulate antigen and a pharmaceutically acceptable carrier, wherein said particulate antigen is of diameter from about 50 to 200 nm and said composition does not ~~comprise~~ contain an adjuvant. ~~cholera toxin or cholera toxoid protein.~~

Claim 2 (previously amended): The method of claim 1 wherein the particulate antigen is an inactivated virus particle.

Claims 3 and 4 (previously canceled)

Claim 5 (previously amended): The method of claim 2 wherein the particulate antigen is about 100 nm in diameter.

Claim 6 (canceled)

Claim 7 (previously amended): The method of claim 2 wherein the inactivated virus particle is selected from the group consisting of an orthomyxovirus particle and a paramyxovirus particle.

Claim 8 (original): The method of claim 7 wherein the inactivated virus particle is an influenza virus particle.

Claim 9 (previously amended): The method of claim 1 wherein the particulate antigen is a virus-like particle.

Claim 10 (previously amended): The method of claim 9 wherein the virus-like particle comprises hemagglutinin.

Claim 11 (previously amended): The method of claim 10 wherein the hemagglutinin is incorporated into the particle by mixed infection with an orthomyxovirus or a paramyxovirus.

Claim 12 (previously amended): The method of claim 2 wherein the particulate antigen comprises mixed inactivated virus particles comprising hemagglutinin which is heterologous to the virus.

Claim 13 (previously amended): The method of claim 12 wherein the hemagglutinin is a recombinant hemagglutinin of influenza virus or parainfluenza virus.

Claim 14 (previously amended): The method of claim 12 where the hemagglutinin is incorporated through mixed infection with an orthomyxovirus or a paramyxovirus.

Claim 15 (previously amended): The method of claim 12 wherein the virus particle is a noninfectious particle of parainfluenza virus, hepatitis C virus, hepatitis virus B, measles virus, vaccinia virus, herpes virus or respiratory syncytium virus.

Claim 16 (original): The method of claim 2 wherein the virus particle has been inactivated by chemical treatment, ultraviolet irradiation, heat treatment or psoralen treatment.

Appl. No. 09/803,649
Amdt. Dated January 20, 2004
Reply to Office Action Of October 22, 2003

Claim 17 (original): The method of claim 16 wherein the chemical treatment is formalin treatment.

Claim 18 (currently amended): A method for inducing an immune response comprising the step of applying to the unbroken surface of the skin a composition comprising a particulate antigen of diameter from about 5 to 200 nm and a pharmaceutically acceptable carrier, wherein said particulate antigen is an inactivated or attenuated virus particle and said composition does not contain an adjuvant, cholera toxin or cholera toxoid protein.

Claims 19 and 20 (canceled)

Claim 21 (currently amended): The method of claim 18 wherein the inactivated or attenuated virus particle contains hemagglutinin.

Claim 22 (original): The method of claim 21 wherein the hemagglutinin is derived from an orthomyxovirus or a paramyxovirus.

Claim 23 (original): The method of claim 22 wherein the hemagglutinin is derived from influenza virus or a parainfluenza virus.

Claim 24 (new): A method for inducing an immune response comprising the step of applying to the unbroken surface of the skin a composition consisting essentially of a particulate antigen and a pharmaceutically acceptable carrier, wherein said particulate antigen is an inactivated influenza virus particle.

Claim 25 (new) The method of claim 24 wherein the influenza virus is inactivated with formalin.